Printer Friendly

Bradykinin inhibitor appears to shorten episodes of hereditary angioedema.

VIENNA -- The investigational bradykinin receptor antagonist icatibant appears to hold considerable therapeutic potential in episodes of hereditary angioedema, Konrad Bork, M.D., said at the annual meeting of the European Society for Dermatological Research.

He presented an open-label, single-center pilot study in which investigators used intravenous icatibant at 0.4 mg/kg beginning within 10 hours after onset of 11 moderate to severe attacks of hereditary angioedema in 10 patients. The patients, each of whom had previously experienced 10-600 similar episodes of angioedema, served as their own historic controls.

Previous episodes in which icatibant wasn't used lasted a mean of 41.3 hours until resolution of symptoms. In contrast, the 11 icatibant-treated episodes lasted a mean of 10.2 hours, reported Dr. Bork of Johannes Gutenberg University, Mainz, Germany. The use of icatibant wasn't associated with any side effects in this study, nor have there been any significant drugrelated side effects reported in more than 700 patients treated to date in clinical trials for various disorders in which bradykinin figures, he said.

Icatibant, a decapeptide, is being developed by Jerini AG of Berlin.
COPYRIGHT 2004 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Jancin, Bruce
Publication:Internal Medicine News
Article Type:Brief Article
Geographic Code:4EUAU
Date:Dec 15, 2004
Previous Article:Rapamycin may reduce SCCs after organ transplantation.
Next Article:Vesicare.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters